Table 1

Association of ALDH1 status with clinicopathological charateristics, stratified by age*.

Characteristic

Patients < 65 years

Patients > 65 years


ALDH1 negative

ALDH1 positive

ALDH1 negative

ALDH1 positive


N

%

N

%

P

N

%

N

%

P


Grade

0.02

0.79


I

19

17.3

18

8.5

11

12.9

13

16.2


II

58

52.7

103

48.6

44

51.8

38

47.5


III

33

30.0

91

42.9

30

35.3

29

36.2


Histological type

0.42

0.20


Ductal

103

92.8

191

90.1

72

84.7

73

91.2


Lobular

8

7.2

21

9.9

13

15.3

7

8.7


Tumor size

0.34

0.55


T1

45

40.2

74

36.1

27

31.0

24

31.6


T2

57

50.9

101

49.3

48

55.2

37

48.7


T3/4

10

8.9

30

14.6

12

13.8

15

19.7


Nodal status

0.02

0.71


Negative

69

62.2

101

47.9

46

56.1

46

59.0


Positive

42

37.8

110

52.1

36

43.9

32

41.0


ER status

0.61

0.01


Negative

43

41.0

91

44.0

16

19.0

30

38.0


Positive

62

59.0

116

56.0

68

81.0

49

62.0


PgR status

0.77

0.08


Negative

48

47.1

84

40.6

26

31.3

35

44.9


Positive

54

52.9

123

59.4

57

68.7

43

55.1


HER2 status

0.99

0.80

Negative

67

87.0

153

86.9

61

93.8

64

92.8


Positive

10

13.0

23

13.1

4

6.2

5

7.2


*Missing data not shown.

Abbreviations: N number of patients; ALDH1 aldehyde dehydrogenase 1; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2

Mieog et al. BMC Cancer 2012 12:42   doi:10.1186/1471-2407-12-42

Open Data